Showing 1 - 9 of 9 results for "04064"
- ReferencePetzer AL et al. (FEB 1996) Proceedings of the National Academy of Sciences of the United States of America 93 4 1470--4
Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.
A major goal of experimental and clinical hematology is the identification of mechanisms and conditions that support the expansion of transplantable hematopoietic stem cells. In normal marrow, such cells appear to be identical to (or represent a subset of) a population referred to as long-term-culture-initiating cells (LTC-ICs) so-named because of their ability to produce colony-forming cell (CFC) progeny for textgreater or = 5 weeks when cocultured with stromal fibroblasts. Some expansion of LTC-ICs in vitro has recently been described, but identification of the factors required and whether LTC-IC self-renewal divisions are involved have remained unresolved issues. To address these issues, we examined the maintenance and/or generation of LTC-ICs from single CD34+ CD38- cells cultured for variable periods under different culture conditions. Analysis of the progeny obtained from cultures containing a feeder layer of murine fibroblasts engineered to produce steel factor, interleukin (IL)-3, and granulocyte colony-stimulating factor showed that approximately 20% of the input LTC-ICs (representing approximately 2% of the original CD34+ CD38- cells) executed self-renewal divisions within a 6-week period. Incubation of the same CD34+ CD38- starting populations as single cells in a defined (serum free) liquid medium supplemented with Flt-3 ligand, steel factor, IL-3, IL-6, granulocyte colony-stimulating factor, and nerve growth factor resulted in the proliferation of initial cells to produce clones of from 4 to 1000 cells within 10 days, approximately 40% of which included textgreater or = 1 LTC-IC. In contrast, in similar cultures containing methylcellulose, input LTC-ICs appeared to persist but not divide. Overall the LTC-IC expansion in the liquid cultures was 30-fold in the first 10 days and 50-fold by the end of another 1-3 weeks. Documentation of human LTC-IC self-renewal in vitro and identification of defined conditions that permit their extensive and rapid amplification should facilitate analysis of the molecular mechanisms underlying these processes and their exploitation for a variety of therapeutic applications. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 05100 MyeloCult™ H5100 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 05100 Product Name: MyeloCult™ H5100 Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO - ReferenceFarese AM et al. (JAN 1996) Blood 87 2 581--91
Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia.
The synthetic cytokine (Synthokine) SC-55494 is a high-affinity interleukin-3 (IL-3) receptor ligand that stimulates greater in vitro multilineage hematopoietic activity than native IL-3, while inducing no significant increase in inflammatory activity relative to native IL-3. The aim of this study was to investigate the in vivo hematopoietic response of rhesus monkeys receiving Synthokine after radiation-induced marrow aplasia. Administration schedule and dose of Synthokine were evaluated. All animals were total-body irradiated (TBI) with 700 cGy 60Co gamma radiation on day 0. Beginning on day 1, cohorts of animals (n = 5) received Synthokine subcutaneously (SC) twice daily with 25 micrograms/kg/d or 100 micrograms/kg/d for 23 days or 100 micrograms/kg/d for 14 days. Control animals (n = 9) received human serum albumin SC once daily at 15 micrograms/kg/d for 23 days. Complete blood counts were monitored for 60 days postirradiation and the durations of neutropenia (NEUT; absolute neutrophil count [ANC] textless 500/microL) and thrombocytopenia (THROM; platelet count textless 20,000/microL) were assessed. Synthokine significantly (P textless .05) reduced the duration of THROM versus the HSA-treated animals regardless of dose or protocol length. The most striking reduction was obtained in the animals receiving 100 micrograms/kg/d for 23 days (THROM = 3.5 v 12.5 days in HSA control animals). Although the duration of NEUT was not significantly altered, the depth of the nadir was significantly lessened in all animal cohorts treated with Synthokine regardless of dose versus schedule length. Bone marrow progenitor cell cultures indicated a beneficial effect of Synthokine on the recovery of granulocyte-macrophage colony-forming units that was significantly higher at day 24 post-TBI in both cohorts treated at 25 and 100 micrograms/kg/d for 23 days relative to the control animals. Plasma pharmacokinetic parameters were evaluated in both normal and irradiated animals. Pharmacokinetic analysis performed in irradiated animals after 1 week of treatment suggests an effect of repetitive Synthokine schedule and/or TBI on distribution and/or elimination of Synthokine. These data show that the Synthokine, SC55 94, administered therapeutically post-TBI, significantly enhanced platelet recovery and modulated neutrophil nadir and may be clinically useful in the treatment of the myeloablated host. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO 04437 MethoCult™ Express Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO Catalog #: 04437 Product Name: MethoCult™ Express - ReferenceConneally E et al. (JAN 1996) Blood 87 2 456--64
Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer.
Recombinant retroviruses offer many advantages for the genetic modification of human hematopoietic cells, although their use in clinical protocols has thus far given disappointing results. There is therefore an important need to develop new strategies that will allow effectively transduced primitive hematopoietic target populations to be both rapidly characterized and isolated free of residual nontransduced but biologically equivalent cells. To address this need, we constructed a murine stem cell virus (MSCV)-based retroviral vector containing the 228-bp coding sequence of the murine heat-stable antigen (HSA) and generated helper virus-free amphotropic MSCV-HSA producer cells by transfection of GP-env AM12 packaging cells. Light density and, in some cases, lineage marker-negative (lin-) normal human marrow or mobilized peripheral blood cells preactivated by exposure to interleukin-3 (IL-3), IL-6, and Steel factor in vitro for 48 hours were then infected by cocultivation with these MSCV-HSA producer cells for a further 48 hours in the presence of the same cytokines. Fluorescence-activated cell sorting (FACS) analysis of the cells 24 hours later showed 21% to 41% (mean, 27%) of those that were still CD34+ to have acquired the ability to express HSA. The extent of gene transfer to erythroid and granulopoietic progenitors (burst-forming unit-erythroid and colony-forming unit-granulocyte-macrophage), as assessed by the ability of these cells to form colonies of mature progeny in the presence of normally toxic concentrations of G418, averaged 11% and 12%, respectively, in 6 experiments. These values could be increased to 100% and 77%, respectively, by prior isolation of the CD34+HSA+ cell fraction and were correspondingly decreased to an average of 2% and 5%, respectively, in the CD34+HSA- cells. In addition, the extent of gene transfer to long-term culture-initiating cells (LTC-IC) was assessed by G418 resistance. The average gene transfer to LTC-IC-derived colony-forming cells in the unsorted population was textless or = 7% in 4 experiments. FACS selection of the initially CD34+HSA+ cells increased this value to 86% and decreased it to 3% for the LTC-IC plated from the CD34+HSA- cells. Transfer of HSA gene expression to a phenotypically defined more primitive subpopulation of CD34+ cells, ie, those expressing little or no CD38, could also be shown by FACS analysis of infected populations 24 hours after infection. These findings underscore the potential use of retroviral vectors encoding HSA for the specific identification and non-toxic selection immediately after infection of retrovirally transduced populations of primitive human hematopoietic cells. In addition, such vectors should facilitate the subsequent tracking of their marked progeny using multiparameter flow cytometry. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO 04437 MethoCult™ Express Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO Catalog #: 04437 Product Name: MethoCult™ Express - ReferenceMayani H et al. (JUN 1993) Blood 81 12 3252--8
Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells.
To study the role of different cytokine combinations on the proliferation and differentiation of highly purified primitive progenitor cells, a serum-free liquid culture system was used in combination with phenotypic and functional analysis of the cells produced in culture. CD34+ CD45RAlo CD71lo cells, purified from umbilical cord blood by flow cytometry and cell sorting, were selected for this study because of their high content of clonogenic cells (34%), particularly multipotent progenitors (CFU-MIX, 12% of all cells). Four cytokine combinations were tested: (1) mast cell growth factor (MGF; a c-kit ligand) and interleukin-6 (IL-6); (2) MGF, IL-6, IL-3, and erythropoietin (Epo); (3) MGF, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF)/IL-3 fusion protein (FP), macrophage colony-stimulating factor (M-CSF), and granulocyte-CSF (G-CSF); and (4) MGF, IL-6, FP, M-CSF, G-CSF, and Epo. Maximum numbers of erythroid progenitors (BFU-E, up to 55-fold increase) and mature erythroid cells were observed in the presence of MGF, IL-6, IL-3, and Epo, whereas maximum levels of myeloid progenitors (CFU-C, up to 70-fold increase) and mature myeloid cells were found in cultures supplemented with MGF, IL-6, FP, M-CSF, and G-CSF. When MGF, IL-6, FP, M-CSF, G-CSF, and Epo were present, maximum levels of both erythroid and myeloid progenitors and their progeny were observed. These results indicate that specific cytokine combinations can act directly on primitive hematopoietic cells resulting in significant expansion of progenitor cell numbers and influencing their overall patterns of proliferation and differentiation. Furthermore, the observations presented in this study suggest that the cytokine combinations used were unable to bias lineage commitment of multipotent progenitors, but rather had a permissive effect on the development of lineage-restricted clonogenic cells. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO - ReferenceYasui K et al. (JAN 2003) Stem cells (Dayton, Ohio) 21 2 143--51
Differences between peripheral blood and cord blood in the kinetics of lineage-restricted hematopoietic cells: implications for delayed platelet recovery following cord blood transplantation.
Cord blood (CB) cells are a useful source of hematopoietic cells for transplantation. The hematopoietic activities of CB cells are different from those of bone marrow and peripheral blood (PB) cells. Platelet recovery is significantly slower after transplantation with CB cells than with cells from other sources. However, the cellular mechanisms underlying these differences have not been elucidated. We compared the surface marker expression profiles of PB and CB hematopoietic cells. We focused on two surface markers of hematopoietic cell immaturity, i.e., CD34 and AC133. In addition to differences in surface marker expression, the PB and CB cells showed nonidentical differentiation pathways from AC133(+)CD34(+) (immature) hematopoietic cells to terminally differentiated cells. The majority of the AC133(+)CD34(+) PB cells initially lost AC133 expression and eventually became AC133(-)CD34(-) cells. In contrast, the AC133(+)CD34(+) CB cells did not go through the intermediate AC133(-)CD34(+) stage and lost both markers simultaneously. Meanwhile, the vast majority of megakaryocyte progenitors were of the AC133(-)CD34(+) phenotype. We conclude that the delayed recovery of platelets after CB transplantation is due to both subpopulation distribution and the process of differentiation from AC133(+)CD34(+) cells. View PublicationCatalog #: Product Name: 04064 Starter Kit for MethoCult™ H4034 Optimum 04960 MegaCult™-C Collagen and Medium Without Cytokines 04961 MegaCult™-C Collagen and Medium with Cytokines 04970 MegaCult™-C Complete Kit Without Cytokines 04971 MegaCult™-C Complete Kit with Cytokines Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04960 Product Name: MegaCult™-C Collagen and Medium Without Cytokines Catalog #: 04961 Product Name: MegaCult™-C Collagen and Medium with Cytokines Catalog #: 04970 Product Name: MegaCult™-C Complete Kit Without Cytokines Catalog #: 04971 Product Name: MegaCult™-C Complete Kit with Cytokines - ReferenceKawano Y et al. (JAN 2003) Blood 101 2 532--40
Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells.
We developed a new human stromal cell line that could expand human hematopoietic progenitor/stem cells. Primary human bone marrow stromal cells were infected with retrovirus containing the human telomerase catalytic subunit (hTERT) gene, resulting in increased population doubling and the acquisition of cell immortalization. Characteristics of the hTERT-transduced stromal (hTERT-stromal) cells were identical with those of the primary stromal cells in terms of morphologic appearance and expression of surface antigens. Human cord blood (CB) CD34(+) cells were expanded by coculture with primary stromal or hTERT-stromal cells in the presence of stem cell factor, thrombopoietin, and Flk-2/Flt-3 ligand under serum-free condition. The degree of expansion of CD34(+) cells and total number of colony-forming units in culture (CFU-Cs) after 2 weeks' coculture with the hTERT-stromal cells were nearly the same as those after 2 weeks' coculture with primary stromal cells (CD34(+) cells, 118-fold +/- 8-fold versus 117-fold +/- 13-fold; CFU-Cs, 71-fold +/- 5-fold versus 67-fold +/- 5-fold of initial cell number). CB expansion on hTERT-stromal cells occurred at a similar rate through 7 weeks. In contrast, the rate of CB expansion on primary stromal cells had drastically declined at 7 weeks. In nonobese diabetic/severe combined immunodeficiency (SCID) mice, the degree of engraftment of SCID-repopulating cells that had been cocultured with hTERT-stromal cells for 4 weeks was significantly higher than that of precocultured CB cells. These results indicate that this hTERT-stromal cell line could be useful for ex vivo expansion of hematopoietic progenitor/stem cells and for analyzing the microenvironment of human bone marrow. View PublicationCatalog #: Product Name: 04064 Starter Kit for MethoCult™ H4034 Optimum 04034 MethoCult™ H4034 Optimum Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum - ReferenceShimakura Y et al. (JAN 2000) Stem cells (Dayton, Ohio) 18 3 183--9
Murine stromal cell line HESS-5 maintains reconstituting ability of Ex vivo-generated hematopoietic stem cells from human bone marrow and cytokine-mobilized peripheral blood.
Human bone marrow (BM) or mobilized peripheral blood (mPB) CD34(+) cells have been shown to loose their stem cell quality during culture period more easily than those from cord blood (CB). We previously reported that human umbilical CB stem cells could effectively be expanded in the presence of human recombinant cytokines and a newly established murine bone marrow stromal cell line HESS-5. In this study we assessed the efficacy of this xenogeneic coculture system using human BM and mPB CD34(+) cells as materials. We measured the generation of CD34(+)CD38(-) cells and colony-forming units, and assessed severe-combined immunodeficient mouse-repopulating cell (SRC) activity using cells five days after serum-free cytokine-containing culture in the presence or the absence of a direct contact with HESS-5 cells. As compared with the stroma-free culture, the xenogeneic coculture was significantly superior on expansion of CD34(+)CD38(-) cells and colony-forming cells and on maintenance of SRC activity. The PKH26 study demonstrated that cell division was promoted faster in cells cocultured with HESS-5 cells than in cells cultured without HESS-5 cells. These results indicate that HESS-5 supports rapid generation of primitive progenitor cells (PPC) and maintains reconstituting ability of newly generated stem cells during ex vivo culture irrespective of the source of samples. This xenogeneic coculture system will be useful for ex vivo manipulation such as gene transduction to promote cell division and the generation of PPC and to prevent loss of stem cell quality. View PublicationCatalog #: Product Name: 04064 Starter Kit for MethoCult™ H4034 Optimum 04034 MethoCult™ H4034 Optimum Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum - ReferenceDonahue RE et al. (JAN 2000) Blood 95 2 445--52
High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells.
We have used a murine retrovirus vector containing an enhanced green fluorescent protein complimentary DNA (EGFP cDNA) to dynamically follow vector-expressing cells in the peripheral blood (PB) of transplanted rhesus macaques. Cytokine mobilized CD34(+) cells were transduced with an amphotropic vector that expressed EGFP and a dihydrofolate reductase cDNA under control of the murine stem cell virus promoter. The transduction protocol used the CH-296 recombinant human fibronectin fragment and relatively high concentrations of the flt-3 ligand and stem cell factor. Following transplantation of the transduced cells, up to 55% EGFP-expressing granulocytes were obtained in the peripheral circulation during the early posttransplant period. This level of myeloid marking, however, decreased to 0.1% or lower within 2 weeks. In contrast, EGFP expression in PB lymphocytes rose from 2%-5% shortly following transplantation to 10% or greater by week 5. After 10 weeks, the level of expression in PB lymphocytes continued to remain at 3%-5% as measured by both flow cytometry and Southern blot analysis, and EGFP expression was observed in CD4(+), CD8(+), CD20(+), and CD16/56(+) lymphocyte subsets. EGFP expression was only transiently detected in red blood cells and platelets soon after transplantation. Such sustained levels of lymphocyte marking may be therapeutic in a number of human gene therapy applications that require targeting of the lymphoid compartment. The transient appearance of EGFP(+) myeloid cells suggests that transduction of a lineage-restricted myeloid progenitor capable of short-term engraftment was obtained with this protocol. (Blood. 2000;95:445-452) View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO - ReferenceGribaldo L et al. (NOV 1999) Experimental hematology 27 11 1593--8
Comparison of in vitro drug-sensitivity of human granulocyte-macrophage progenitors from two different origins: umbilical cord blood and bone marrow.
Predictive in vitro hematotoxicity assays using human cells will provide estimation of tolerable level and aid considerably the development of agents with greater therapeutic activity and less toxicity. Human hematopoietic cells can be derived from three sources: human bone marrow by sternal or femoral aspiration, mobilized peripheral blood, or umbilical cord blood samples collected from placentas after deliveries. Because of the difficulties to have a continuous supply of bone marrow cells from normal human donors and the related ethical problems, we performed a study to compare the sensitivity of human bone marrow cells (h-BMC) and human cord blood cells (h-CBC) to chemicals in order to confirm if h-CBC can readily replace bone marrow cells in checking the sensitivity of GM-CFU progenitors to drugs as preliminarily reported in literature. Our results showed that the prediction of IC50 values in human model is quite similar by using h-BMC or h-CBC. On the contrary, the type of medium influenced in a significant way the ICs determination of some drugs. View PublicationCatalog #: Product Name: 04436 MethoCult™ SF H4436 04064 Starter Kit for MethoCult™ H4034 Optimum 04100 MethoCult™ H4100 04230 MethoCult™ H4230 04236 MethoCult™ SF H4236 04431 MethoCult™ H4431 04434 MethoCult™ H4434 Classic 04464 Starter Kit for MethoCult™ H4434 Classic 04531 MethoCult™ H4531 04535 MethoCult™ H4535 Enriched Without EPO 04536 MethoCult™ SF H4536 04564 Starter Kit for MethoCult™ H4534 Classic Without EPO 04035 MethoCult™ H4035 Optimum Without EPO 04330 MethoCult™ H4330 04034 MethoCult™ H4034 Optimum 04435 MethoCult™ H4435 Enriched 04534 MethoCult™ H4534 Classic Without EPO Catalog #: 04436 Product Name: MethoCult™ SF H4436 Catalog #: 04064 Product Name: Starter Kit for MethoCult™ H4034 Optimum Catalog #: 04100 Product Name: MethoCult™ H4100 Catalog #: 04230 Product Name: MethoCult™ H4230 Catalog #: 04236 Product Name: MethoCult™ SF H4236 Catalog #: 04431 Product Name: MethoCult™ H4431 Catalog #: 04434 Product Name: MethoCult™ H4434 Classic Catalog #: 04464 Product Name: Starter Kit for MethoCult™ H4434 Classic Catalog #: 04531 Product Name: MethoCult™ H4531 Catalog #: 04535 Product Name: MethoCult™ H4535 Enriched Without EPO Catalog #: 04536 Product Name: MethoCult™ SF H4536 Catalog #: 04564 Product Name: Starter Kit for MethoCult™ H4534 Classic Without EPO Catalog #: 04035 Product Name: MethoCult™ H4035 Optimum Without EPO Catalog #: 04330 Product Name: MethoCult™ H4330 Catalog #: 04034 Product Name: MethoCult™ H4034 Optimum Catalog #: 04435 Product Name: MethoCult™ H4435 Enriched Catalog #: 04534 Product Name: MethoCult™ H4534 Classic Without EPO
Shop By
Filter Results
Filters:
- Resource Type Reference Remove This Item
- Clear All
- Area of Interest
- Cord Blood Banking 1 item
- Stem Cell Biology 3 items
- Transplantation Research 3 items
- Brand
- MegaCult 1 item
- MethoCult 8 items
- MyeloCult 1 item
- Cell Type
- Hematopoietic Stem and Progenitor Cells 3 items
- Myeloid Cells 1 item